American Journal of Kidney Diseases
Volume 45, Issue 3 , Pages 531-539 , March 2005

Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population

  • Consuelo Huerta, MD

      Affiliations

    • Centro Español de Investigación Farmacoepidemiológica, Spanish Centre for Pharmacoepidemiologic Research, Madrid, Spain
    • Corresponding Author InformationAddress reprint requests to Consuelo Huerta Alvarez, MD, Centro Español de Investigación Farmacoepidemiológica (CEIFE), Almirante 28; 2°, 28004 Madrid, Spain
    • ,
  • Jordi Castellsague, MD

      Affiliations

    • Pfizer Global Epidemiology, Safety and Risk Management, Barcelona, Spain
    • ,
  • Cristina Varas-Lorenzo, MD, PhD

      Affiliations

    • Pfizer Global Epidemiology, Safety and Risk Management, Barcelona, Spain
    • ,
  • Luis Alberto García Rodríguez, MD

      Affiliations

    • Centro Español de Investigación Farmacoepidemiológica, Spanish Centre for Pharmacoepidemiologic Research, Madrid, Spain

Received 13 October 2004 ,Accepted 2 December 2004.

References 

  1. De Broe ME , Elseviers MM . Analgesic nephropathy . N Engl J Med . 1998;338:446–452
  2. Bennett WM , Henrich WL , Stoff JS . The renal effects of nonsteroidal anti-inflammatory drugs (Summary and recommendations) . Am J Kidney Dis . 1996;28(suppl 1):S56–S62
  3. Delmas PD . Non-steroidal anti-inflammatory drugs and renal function . Br J Rheumatol . 1995;34(suppl 1):S25–S28
  4. Epstein M . Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction . J Hypertens . 2002;20(suppl 6):S17–S23
  5. Gambaro G , Perazella MA . Adverse renal effects of anti-inflammatory agents (Evaluation of selective and nonselective cyclooxygenase inhibitors) . J Intern Med . 2003;253:643–652
  6. Murray MD , Brater DC . Renal toxicity of the nonsteroidal anti-inflammatory drugs . Annu Rev Pharmacol Toxicol . 1993;33:435–465
  7. Radford MG , Holley KE , Grande JP , et al.   Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs . JAMA . 1996;276:466–469
  8. Warren GV , Korbet SM , Schwartz MM , Lewis EJ . Minimal change glomerulopathy associated with nonsteroidal anti-inflammatory drugs . Am J Kidney Dis . 1989;13:127–130
  9. Beard K , Perera DR , Jick H . Drug-induced parenchymal renal disease in outpatients . J Clin Pharmacol . 1988;28:431–435
  10. Guess HA , Strand LM , Helston N , Lydick E , Bergman U , Wolski K . Hospitalizations for renal impairment among users and non-users of non-steroidal anti-inflammatory drugs in Saskatchewan, Canada, 1983 . In:  Rainsford KD ,  Velo GP editor. Side-Effects of Anti-Inflammatory Drugs, Part 2 . Lancaster, UK: MTP; 1985;p. 367–374
  11. Beard K , Lawson DH , MacFarlane GJ . Non-steroidal anti-inflammatory drugs and acute renal disease (A case-control study) . Pharmacoepidemiol Drug Safety . 1992;1:3–9
  12. Evans JMM , McGregor E , McMahon AD , et al.   Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure . Q J Med . 1995;88:551–557
  13. Pérez Gutthann S , García Rodríguez LA , Raiford DS , Duque Oliart A , Ris Romeu J . Non-steroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure . Arch Intern Med . 1996;156:2433–2439
  14. Henry D , Page J , Whyte I , Nanra R , Hall C . Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects (Results of a case-control study) . Br J Clin Pharmacol . 1997;44:85–90
  15. Griffin MR , Yared A , Ray WA . Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons . Am J Epidemiol . 2000;151:488–496
  16. García Rodríguez LA , Pérez Gutthann S . Use of the UK General Practice Research Database for pharmacoepidemiology . Br J Clin Pharmacol . 1998;45:419–426
  17. García Rodríguez LA , Pérez Gutthann S , Jick S . The UK General Practice Research Database . In:  Strom BL editors. Pharmacoepidemiology . ed 3. Chichester, England: Wiley; 2000;p. 375–385
  18. Jick H , Jick SS , Derby LE . Validation of information recorded on general practitioner based computerised data resource in the United Kingdom . BMJ . 1991;302:766–768
  19. Pérez Gutthann S , García Rodríguez LA , Duque-Oliart A , Varas-Lorenzo C . Low-dose diclofenac, naproxen, and ibuprofen cohort study . Pharmacotherapy . 1999;19:854–859
  20. Vigeral P , Baumelou A , Benichou C , et al.   Les insuffisances rénales d’origine médicamenteuse (Resultants de reunions de consensus) . Nephrologie . 1989;10:157–161
  21. Hardman JG , Limbird LE , Molinoff PB , Ruddon RW , Goodman-Gilman A . Goodman & Gilman’s The Pharmacological Basis of Therapeutics . New York, NY: McGraw-Hill; 1996;
  22. Rothman KJ . Modern Epidemiology . ed 1. Boston, MA: Little, Brown; 1986;
  23. Hosmer DW , Lemeshow S . Confidence interval estimation of interaction . Epidemiology . 1992;3:452–456
  24. Berry C , McMurray JJV . Serious adverse events experienced by patients with chronic heart failure taking spironolactone . Heart . 2001;85:E8
  25. Bridoux F , Hazzan M , Pallot JL , et al.   Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis . Nephrol Dial Transplant . 1992;7:100–104
  26. Bennet WM , Henrich WL , Stoff JS . The renal effects of nonsteroidal anti-inflammatory drugs (Summary and recommendations) . Am J Kidney Dis . 1996;28(suppl 1):S56–S62
  27. Whelton A . Nephrotoxicity of nonsteroidal anti-inflammatory drugs (Physiologic foundation and clinical implications) . Am J Med . 1999;106(suppl):13S–24S
  28. Brater C . Diuretic therapy . N Engl J Med . 2004;339:387–395
  29. Ulcickas YM , Rothman K , Johnson C , et al.   Using prescription claims for drugs available over-the-counter (OTC) . Pharmacoepidemiol Drug Safety . 2000;9(suppl):S37; (abstr 099)
  30. MacDonald TM , Beard K , Bruppacher R , et al.   The safety of drugs for OTC use (What evidence is required for an NSAID switch?) . Pharmacoepidemiol Drug Safety . 2002;11:577–584

 Originally published online as doi:10.1053/j.ajkd.2004.12.005 on January 26, 2005.

 Supported in part by an unrestricted research grant from Pfizer. The design and analysis of this study were made independently by Centro Español de Investigación Farmacoepidemiológica.

PII: S0272-6386(04)01619-1

doi: 10.1053/j.ajkd.2004.12.005

American Journal of Kidney Diseases
Volume 45, Issue 3 , Pages 531-539 , March 2005

Article Tools